Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
Treadwell Therapeutics
About
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $91M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2020
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 18, 2021 | Series B | $91M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Prosperous Alliance Investments
|
— | Series B |
|
|
— | Series B |
